Member Info for WeTookPelham

https://www.telegraph.co.uk/news/2022/07/15/covid-omicron-variant-troubling-people-arent-responding-vaccines/

https://www.labiotech.eu/trends-news/beyond-biotech-podcast-2/

Big pharma better get their skates on if Bezo's billions are on it. A cheeky M&A or partnership with a certain UK small bio might speed up things?

https://www.theguardian.com/world/2022/jul/12/centaurus-virologists-express-concern-at-new-covid-subvariant-omicron

"...In addition to its apparent rapid growth and wide geographical spread, virologists have been alerted by the sheer number of extra mutations BA.2.75 contains, relative to BA.2, from which it is likely to have evolved. “This could mean that it has had the chance to evolve an advantage over an already successful virus lineage, said Dr Stephen Griffin, a virologist at the University of Leeds.

“It’s not so much the exact mutations, more the number/combination,” said Dr Tom Pea****, a virologist at Imperial College London, who was the first to identify Omicron as a potential concern back in November 2021. “It’s hard to predict the effect of that many mutations appearing together – it gives the virus a bit of a ‘wildcard’ property where the sum of the parts could be worse than the parts individually."

@lofas....I'm curious, are you invested here? (Sclp I mean).

Edit - just checked, job titles are the same.

...now mentioned on the Scancell website:

https://www.scancell.co.uk/careers

I feel like the job titles have changed a little?

https://www.nature.com/articles/s41564-022-01143-7

"...Here we demonstrate substantial evasion of neutralization by Omicron BA.1 and BA.2 variants in vitro using sera from individuals vaccinated with ChAdOx1, BNT162b2 and mRNA-1273. These data were mirrored by a substantial reduction in real-world vaccine effectiveness that was partially restored by booster vaccination."

5/6 of those trades are very close together, so just stop losses? Seem to have an air of automation to me IMO.

Absolutely nailed it @mattrepit.
The whole handling of the vaccines by uk gov wreaked of the same stench RE their handling of PPE IMO.
Somewhere along the line it was snouts in the trough.

Good spot Chester18.

Agree, it does seem odd we've not had our turn "yet".

I thought however that they keep approaches/bids by third parties to themselves until they mention it later, e.g. at AGMs to individuals or at proactive presentations?

Are they obliged to mention these?

Watching the news and Covid seems to be back front and centre.
Also (purely IMO) it shows that the 1st generation vaccines were nothing more than a temporary stopgap.
There could be renewed interest here IMO.

https://www.theguardian.com/world/2022/jul/02/uk-scientists-warn-of-urgent-need-for-action-on-vaccines-to-head-off-autumn-covid-wave

Agree Roses. For example we don't know any of 4(?) companies using the mABs do we.
And IMO if we knew who the big euro pharma was i think there would be a lot more attention here.

Intricacies of web/url formats aside, that article is interesting for Scancell as (IMO) they have 3/4 x platforms/eco systems that each stand up on their own right, and could make a company in their own right, when you stand back and think about:
-Moditope
-Immunobody
-GlyMab
-Avidimab.

I'm sure there are some bio companies that would be happy just to have one of those as their only platform, and hence why I'm sure there is lots of interest that we don't know about.

The mabs side seems the most immediate to "branch off" with the set up of Zakari?

Edit - try this link instead:

https://www.fiercepharma.com/pharma/ma-landscape-tilting-away-late-stage-buys-and-toward-platform-strategy-analysts

"01/7/2022
20:39 ivyspivey: hTTps://www.fiercepharma.com/pharma/ma-landscape-tilting-away-late-stage-buys-and-toward-platform-strategy-analysts
May be of interest as platforms become more important."

https://www.bbc.co.uk/news/live/uk-62008118

"LIVE Covid cases up 32% as Omicron sub-variants drive infections"

If I was BionTech with billions sloshing around in their petty cash funds and I had existing relationship, I would certainly consider having a "DNA" arm/partner of the business, to expand their portfolio/cover all the bases...IMO. But maybe like you say, just want to stick to mRNA, who knows.